Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis

The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis.

Anticipated result is to prove superiority of Rebamipide/Nizatidine combination therapy at 2 weeks compared to Nizatidine Monotherapy.

Inclusion criteria

• Male or female aged 19 years or older and under 75 years
• Subject who was diagnosed with acute or chronic gastritis in upper gastrointestinal endoscopy conducted within 7 days prior to the start of administration of medications for clinical trials and identified at least one labyrinth (defect of mucosal surface layer)
• Subject who voluntarily decides to participate in the trial after hearing the explanation of this clinical trial and signs the informed consent form.

Exclusion criteria

• Subject who is unable to examine the upper gastrointestinal endoscope
• A person with the following past history

• Surgery to suppress gastric acid secretion or gastrointestinal and esophagus surgery
• Malignant tumor of the digestive system
• overreacted to the components of medicine for clinical trials and H2 receptor blockers
• Drug or alcohol abuse
• A person accompanied by the following diseases

• Digestive ulcers (excluding half a scar)
• Reflux esophagitis
• Inflammatory bowel disease (cron disease, ulcerative colitis)
• Thrombotic diseases (such as cerebral thrombosis, myocardial infarction, thrombotic venous inflammation, etc.)
• Zollinger-Ellison syndrome
• Subject with mental illness, cardiovascular system, respiratory system, endocrine system, central nervous system who the investigator determined that it is difficult to participate in this clinical trial
• A person who needs to administer a taboo drug during the clinical trial period.
• Pregnant women and nursing women
• Fertilized women and men who have a pregnancy plan or do not have the will to use the appropriate contraceptive method during the clinical trial period.
• Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc.
• Severe liver disorder (AST or ALT > 3 times the normal upper limit of the organ)
• Serious nephropathy (creatinine clearance < 50 mL/min)
• Subject who has been administered (applied) other clinical medications or medical devices within 4 weeks of screening
• Subject who the investigator determined it is inappropriate to participate in this clinical trial.